Quantitation of secretory component levels in cyst fluids, ascitic fluids, and sera from ovarian adenocarcinoma patients

Quantitation of immunoglobulins in the effusions of human ovarian epithelial neoplasms

Cyst and ascites fluid was obtained from 31 different patients with ovarian epithelial neoplasms and was analyzed for the molecular forms and quantities of IgG, IgM, and IgA. The fluids were grouped on the basis of the pathologic diagnosis of the tumor tissue for investigation of the possibility that immunoglobulin levels in fluids from ovarian neoplasms varied with the type of tumor. Immunoglobulin concentrations in most cyst fluid samples were comparable to amounts detected in normal human serum; however, significant reductions in the amounts of IgA in fluids from mucinous cystadenocarcinomas and in the amounts of both IgA and IgM in fluids from mucinous cystadenoma were demonstrated. The cyst fluid immunoglobulins were present in the same molecular forms as serum immunoglobulins, that is, pentameric IgM, predominantly monomeric IgA, and monomeric IgG. The usefulness of cyst effusions as a source of autologous antibodies in the investigation of the immune response to tumors is discussed.

Study of secretory component in patients with metastatic breast cancer

A radioimmunoassay was developed for secretory component, a glandular epithelial cell product secreted as an accessory protein with dimeric immunoglobulins A and M. Forty-four normal women between the ages of 40 and 70 had plasma concentrations of secretory component of 7.195 microgram/ml +/- 3.590 (+/-2 SD). Of the patients with metastic breast cancer of epithelial origin, 34 (91.9%) had plasma concentrations greater than 8.990 microgram/ml; 29 (78.1%) had plasma concentrations greater than 10.785 microgram/ml; 10 (27%) had concentrations greater than 15.000 microgram/ml; and 3 (8.1%) had concentrations greater than 22.710 microgram/ml. Serial plasma concentrations (averaging 3.48 per patient) of 35 (94.6%) of these patients reflected the clinical course of the disease. All patients had some combination of surgery, radiation therapy, and chemotherapy. No direct correlation was noted between the type of therapy and concentration of secretory component. However, plasma secretory component served as a marker in the systemic circulation of a change in the status of the metastatic breast cancer. The impact of this research may lie in its incorporation into clinical management.